At least one disgruntled co-author has triggered the retraction of a paper presenting a novel approach to treating a rare, genetically inherited condition.
The paper concerned research on Fragile X syndrome (FXS), characterized by both intellectual and physical abnormalities, which is linked autism. A compound that passed through phase 2 clinical trials in October 2015 appeared to partially treat FXS in mice in the study, published earlier this year.
The journal’s notice says the paper was retracted over a dispute among authors about the order in which they are listed on the paper: Continue reading Dispute over author order torpedoes paper on syndrome linked to autism
In February 2016,
Got $300? Then you can be added as an author to a paper — even if you had no role in the research. 

A group of researchers have retracted their 2016 case report about a rare dermatologic disorder in the wake of disputes about authorship and institutional approval.


